Lanifibranor vs Pioglitazone
Written by Aaron CuhaReviewed Sep 2026
The short answer
Both act on PPAR switches and both have been tested in fatty liver disease. Pioglitazone is approved for diabetes, is cheap, and carries a boxed warning for heart failure. Lanifibranor is still in testing and hits all three types of PPAR switch rather than one.
- Lanifibranor people
- 0
- Lanifibranor nulls
- 0
- Pioglitazone people
- 9,114
- Pioglitazone nulls
- 1
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
LanifibranorLanifibranor, pan-PPAR agonist
A daily pill for fatty liver disease that works on all three PPAR switches. Its 1,000-person final-stage study finished in September 2026, with results due by the end of the year.
Column B
PioglitazonePioglitazone (Actos), thiazolidinedione PPAR-gamma agonist
An approved diabetes drug with real heart and stroke data in people. In the 2026 mouse lifespan run, it was one of two compounds that shortened female lifespan in the check that held up after leaving out an odd lab.
Side by side, on the facts we can check
| What we compare | Lanifibranor | Pioglitazone |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; a final-stage study has finished giving doses | FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use. |
| Half-life | Once-daily oral dosing | Three to seven hours for the parent compound, with active metabolites extending to roughly 16 to 24 hours, which supports once-daily dosing. |
| Molecular weight | 434.9 Da | 356.4 Da. A small molecule, not a peptide. |
| How it works | It switches on all three PPAR receptors. That improves how the liver handles fat, and it calms inflammation and the cells that lay down scar tissue. | Pioglitazone switches on PPAR-gamma, a control switch inside cells found mostly in fat tissue. That makes new small fat cells that respond well to insulin. It moves fat out of the liver and muscle, and lowers free fatty acids in the blood. That is how it makes the whole body more sensitive to insulin. The same switch makes the kidney hold on to salt, which causes the swelling and the heart failure risk. It also pushes stem cells in the bone marrow to become fat instead of bone, the likely route to the broken bone risk. |
| Studies in people | 2 | 2 |
| Evidence | Limited: 1 completed trial, none stating how many people | Strong: 2 completed trials, 9,114 people given it |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Lanifibranor and Pioglitazone?
Lanifibranor: A daily pill for fatty liver disease that works on all three PPAR switches. Its 1,000-person final-stage study finished in September 2026, with results due by the end of the year. Pioglitazone: An approved diabetes drug with real heart and stroke data in people. In the 2026 mouse lifespan run, it was one of two compounds that shortened female lifespan in the check that held up after leaving out an odd lab.
Which has stronger research evidence, Lanifibranor or Pioglitazone?
Each compound gets a band worked out from facts we counted, with the math shown. Lanifibranor is Limited (1 completed trial, none stating how many people). Pioglitazone is Strong (2 completed trials, 9,114 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Lanifibranor and Pioglitazone FDA-approved?
Lanifibranor: Investigational; a final-stage study has finished giving doses. Pioglitazone: FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use..
Related posts
Blog articles that cover Lanifibranor or Pioglitazone, newest first.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.